INT145884

From wiki-pain
Revision as of 02:27, 23 September 2012 by Daniel (Talk | contribs)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2007
Last Reported 2008
Negated 2
Speculated 0
Reported most in Body
Documents 19
Total Number 28
Disease Relevance 12.67
Pain Relevance 1.72

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (SH3GL3) endosome (SH3GL3) signal transduction (SH3GL3)
cytoplasm (SH3GL3)
Anatomy Link Frequency
plasma 8
urine 4
endothelial cells 2
myocytes 1
brain 1
SH3GL3 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 163 99.12 Very High Very High Very High
Paracetamol 22 95.12 Very High Very High Very High
Central nervous system 61 94.44 High High
Potency 6 83.04 Quite High
corticosteroid 11 78.36 Quite High
Antihistamine 11 77.60 Quite High
cva 56 76.84 Quite High
fibrosis 60 67.92 Quite High
ischemia 21 66.08 Quite High
headache 6 62.56 Quite High
Disease Link Frequency Relevance Heat
Pain 214 99.12 Very High Very High Very High
Fabry Disease 768 98.92 Very High Very High Very High
Coronary Heart Disease 89 98.88 Very High Very High Very High
Disorders Of Creatine Metabolism 56 97.90 Very High Very High Very High
Renal Disease 472 97.64 Very High Very High Very High
Chronic Renal Failure 211 95.36 Very High Very High Very High
Cv General 2 Under Development 30 94.44 High High
Sensorineural Hearing Loss 55 94.40 High High
Proteinuria 901 94.04 High High
Disease 440 93.96 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The clinical efficacy of ERT was associated with stabilization of renal function, a significant reduction in the GL-3 level, and improvement in renal pathology (34).
Negative_regulation (reduction) of GL-3
1) Confidence 0.43 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.62 Pain Relevance 0.15
The following were observed: a lowering of the plasma levels of GL-3 in seven cases, an improvement in the daily activities in six cases, and a reduction in corneal clouding in three cases.
Negative_regulation (lowering) of GL-3 in plasma
2) Confidence 0.42 Published 2007 Journal J. Int. Med. Res. Section Abstract Doc Link 17697536 Disease Relevance 0.49 Pain Relevance 0.08
Although the period of treatment and the age of the subjects vary considerably, ERT is safe and effective in stabilizing renal functions, decreasing GL-3 levels in plasma and urine, and clearing GL-3 deposits from kidney biopsy specimens without significant adverse events in patients with Fabry disease.
Negative_regulation (decreasing) of GL-3 in kidney associated with fabry disease
3) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.48 Pain Relevance 0.08
Despite decreased plasma and urine GL-3 levels, there were no significant changes in urinary protein excretion and serum creatinine levels.
Negative_regulation (decreased) of urine GL-3 in urine
4) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.24 Pain Relevance 0.10
The GL-3 levels were reduced to the normal range within 3 to 6 months of ERT onset, with the exception of two patients (patients 4 and 11) (Fig. 2A).
Negative_regulation (reduced) of GL-3
5) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.75 Pain Relevance 0
In patients 1 and 6, the GL-3 deposition was markedly decreased in the vascular endothelial cells after ERT, although the glomerular and tubulointerstitial features were not changed (Fig. 3).
Negative_regulation (decreased) of GL-3 in endothelial cells
6) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.35 Pain Relevance 0.06
However, in patient 7, the GL-3 deposition in the vascular endothelial cells was not decreased and the glomerular and tubulointerstitial changes were advanced.


Neg (not) Negative_regulation (decreased) of GL-3 in endothelial cells
7) Confidence 0.32 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.39 Pain Relevance 0.08
In summary, this study demonstrates that the clinical effects of ERT were associated with a significant reduction in the serum and urine GL-3 levels, and clearance of the accumulated GL-3 from the vascular endothelium of biopsied kidney.
Negative_regulation (reduction) of urine GL-3 in urine
8) Confidence 0.31 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.29 Pain Relevance 0.17
Plasma and urine GL-3 levels were reduced within 3 to 6 months of ERT initiation.
Negative_regulation (reduced) of urine GL-3 in urine
9) Confidence 0.28 Published 2008 Journal Journal of Korean Medical Science Section Abstract Doc Link PMC2526436 Disease Relevance 0.57 Pain Relevance 0
Microvascular endothelial deposits of GL-3 were decreased from renal biopsy specimens after 1 yr of treatment.
Negative_regulation (decreased) of GL-3
10) Confidence 0.28 Published 2008 Journal Journal of Korean Medical Science Section Abstract Doc Link PMC2526436 Disease Relevance 0.56 Pain Relevance 0
Therefore, reduction in GL-3 inclusions did not predict clinical efficacy, and therefore resolution of GL-3 did not fulfill the criteria for a validated surrogate marker (Fleming 2005).
Negative_regulation (reduction) of GL-3
11) Confidence 0.14 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.12 Pain Relevance 0.05
Plasma GL-3 levels were reduced to normal by 6 months in the active-treatment group, and were maintained at these levels throughout the study.
Negative_regulation (reduced) of GL-3 in Plasma
12) Confidence 0.14 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.24 Pain Relevance 0
The secondary outcome measures include reductions in plasma and urinary GL-3 levels.


Negative_regulation (reductions) of GL-3 in plasma
13) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.49 Pain Relevance 0
Most affected males have little, if any, alpha-galactosidase A activity, and the deposition of GL-3 occurs primarily in vascular endothelial cells as well as epithelial and smooth muscle cells throughout the body.
Negative_regulation (deposition) of GL-3 in body
14) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.77 Pain Relevance 0.12
In these biopsy studies, significant deposition of GL-3 was found in glomeruli, as well as the tubulo-interstitial and vascular compartments long before overt Fabry nephropathy was manifested clinically (Gubler et al 1978; Tondel et al 2008; Valbuena et al 2008).
Negative_regulation (deposition) of GL-3 associated with renal disease
15) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.68 Pain Relevance 0.03
The “cardiac” variant of Fabry disease refers to patients who have some residual alpha-galactosidase A activity, with GL-3 deposition confined to myocytes, and as first described, do not manifest the whole spectrum of symptoms present in classical Fabry disease (von Scheidt et al 1991; Nakao et al 1995).
Negative_regulation (deposition) of GL-3 in myocytes associated with fabry disease
16) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 1.16 Pain Relevance 0
Despite decreased plasma and urine GL-3 levels, there were no significant changes in urinary protein excretion and serum creatinine levels.
Negative_regulation (decreased) of urine GL-3 in plasma
17) Confidence 0.11 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2526436 Disease Relevance 0.24 Pain Relevance 0.10
B) Are the underlying pathophysiologic processes improved in parallel with reductions in the GL-3 load?
Negative_regulation (reductions) of GL-3
18) Confidence 0.10 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.22 Pain Relevance 0.03
Plasma GL-3 decreased in the active-treatment group, and was unchanged in the placebo-treated group.
Negative_regulation (decreased) of GL-3 in Plasma
19) Confidence 0.10 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0.38 Pain Relevance 0.11
Urinary clearance of GL-3 was impaired in antibody-positive patients treated with 0.2 mg/kg ERT, confirming previous observations (Linthorst et al 2004; Schiffmann et al 2006), but this finding has not been shown to correlate with any differences in clinical outcomes in prospective studies.
Negative_regulation (impaired) of GL-3
20) Confidence 0.10 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727881 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox